Recombinant Human Bone Marrow Proteoglycan/BMPG (C-His)

Catalog No: BP028 (C818)

Description	Recombinant Human Bone Marrow Proteoglycan is produced by Human cells system and the target gene encoding Leu17-Tyr222 is expressed with a 6His tag at the C-terminus.
Expression System	Human cells
Alternative name	Bone Marrow Proteoglycan; BMPG; Proteoglycan 2; Eosinophil Granule Major Basic Protein; EMBP; MBP; Pregnancy-Associated Major Basic Protein; PRG2; MBP
Accession No.	P13727
Predicted Molecular Weight	24.4kDa
Apparent Molecular Weight	25-35kDa, reducing conditions.
Quality Control	Purity: greater than 95% as determined by reducing SDS-PAGE. Endotoxin: less than 0.1 ng/μg (1 EU/μg) as determined by LAL test.
Formulation	Supplied as a 0.2 um filtered solution 20mM PB, 150mM NaCl, pH 7.4
Shipping	The product is shipped on dry ice pack. Upon receipt, store it immediately at the temperature listed below.
Storage	Store at < -20°C, stable for 6 months after receipt. Please minimize freeze-thaw cycles.
Background	Bone Marrow Proteoglycan (BMPG) is a secreted protein that contains one C-type lectin domain. BMPG is the predominant constituent of the crystalline core of the eosinophil granule. BMPG is highly expressed in placenta and pregnancy serum. BMPG may be involved in antiparasitic defense mechanisms as a cytotoxin and helminthotoxin. BMPG induces non-cytolytic histamine release from human basophils. In addition, BMPG also participated in antiparasitic defense mechanisms and immune hypersensitivity reactions.

SDS-PAGE



1: Reducing condition

2: Non-reducing condition